1.
Provider communication and HPV vaccination: The impact of recommendation quality
by Gilkey, Melissa B
Vaccine, 2016, Vol.34 (9), p.1187-1192
2.
Human papillomavirus and cervical cancer
by Crosbie, Emma J, PhD
The Lancet (British edition), 2013, Vol.382 (9895), p.889-899
3.
Do correlates of HPV vaccine initiation differ between adolescent boys and girls?
by Gilkey, Melissa B
Vaccine, 2012, Vol.30 (41), p.5928-5934
4.
The impact of HPV multi-cohort vaccination: Real-world evidence of faster control of HPV-related morbidity
by Orumaa, Madleen
Vaccine, 2020-02-05, Vol.38 (6), p.1345-1351
5.
Provider response and follow-up to parental declination of HPV vaccination
by Margolis, Marjorie A
Vaccine, 2022-01-21, Vol.40 (2), p.344-350
6.
Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis
by Drolet, Mélanie, PhD
The Lancet infectious diseases, 2015, Vol.15 (5), p.565-580
7.
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of t...
by Wheeler, Cosette M, Dr, Prof
The lancet oncology, 2012, Vol.13 (1), p.100-110
8.
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PA...
by Lehtinen, Matti, Prof
The lancet oncology, 2012, Vol.13 (1), p.89-99
9.
A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines
by Schiller, John T
Vaccine, 2012, Vol.30 (5), p.F123-F138
10.
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial
by Huh, Warner K
The Lancet (British edition), 2017-11-11, Vol.390 (10108), p.2143-2159
11.
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
by de Sanjose, Silvia, Dr
The lancet oncology, 2010, Vol.11 (11), p.1048-1056
12.
Evidence Regarding Human Papillomavirus Testing in Secondary Prevention of Cervical Cancer
by Arbyn, Marc
Vaccine, 2012, Vol.30 (Suppl 5), p.F88-F99
13.
Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials
by Ronco, Guglielmo, Dr
The Lancet (British edition), 2014-02-08, Vol.383 (9916), p.524-532
14.
Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study
by Sankaranarayanan, Rengaswamy, Dr
The lancet oncology, 2016, Vol.17 (1), p.67-77
15.
Human papillomavirus vaccines: WHO position paper, May 2017–Recommendations
by World Health Organization
Vaccine, 2017, Vol.35 (43), p.5753-5755
16.
Evidence for single-dose protection by the bivalent HPV vaccine—Review of the Costa Rica HPV vaccine trial and future research studies
by Kreimer, Aimée R
Vaccine, 2018-08-06, Vol.36 (32), p.4774-4782
17.
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a p...
by Paavonen, Jorma, Prof
The Lancet (British edition), 2007, Vol.369 (9580), p.2161-2170
18.
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials
by Kreimer, Aimée R, Dr
The lancet oncology, 2015, Vol.16 (7), p.775-786
19.
Human Papillomavirus Vaccine Introduction – The First Five Years
by Markowitz, Lauri E
Vaccine, 2012, Vol.30, p.F139-F148
20.
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind,...
by Skinner, S Rachel, PhD
The Lancet (British edition), 2014, Vol.384 (9961), p.2213-2227
